Diligence memo · auto-generated · as of July 2, 2026
Rib X Pharmaceuticals Inc
Rib X Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Rib X Pharmaceuticals Inc operates in Pharmaceuticals, based in NEW HAVEN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Rib X Pharmaceuticals Inc has raised $30M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $19M on 2012-11-15.
Most recent recorded round closed around 2012-11-15.
Valuation (modeled)modeled
Provath models Rib X Pharmaceuticals Inc at approximately $635M (range $39M–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.86× the median modeled value of Series B Pharmaceuticals companies in 2010–2012 (47 peers) — value vs value, same stage and era. Within the normal band (86% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 13.6 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 3.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 73% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 83% of those peers.
Closest niche peers: Celator Pharmaceuticals Inc, Kythera Biopharmaceuticals Inc, Palatin Technologies Inc, Pernix Therapeutics Holdings, Inc., CEBIX Inc.
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.